Daily Endocrinology Research Analysis
Analyzed 43 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology papers stood out: a mechanistic study uncovered an extracellular vesicle-mediated mitochondrial quality control network between Leydig cells and testicular macrophages essential for testosterone synthesis; another revealed beta cell-derived cholecystokinin as a driver of obesity-associated pancreatic adenocarcinoma; and a large target-trial emulation compared sulfonylurea safety, informing drug selection in type 2 diabetes.
Research Themes
- Organelle quality control in endocrine steroidogenesis
- Endocrine–exocrine crosstalk driving tumorigenesis
- Real-world comparative safety of glucose-lowering therapies
Selected Articles
1. Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development.
In mouse models, β-cell expression of cholecystokinin (CCK) was necessary and sufficient to drive obesity-associated PDAC, correlating more strongly with tumorigenesis than insulin. Obesity expanded immature β cells that adopted CCK expression via JNK/cJun signaling, altering peri-islet exocrine states and promoting islet-proximal tumor formation.
Impact: This study reframes the endocrine contribution to PDAC by identifying β-cell CCK—not insulin—as a causal driver, opening a new therapeutic axis at the endocrine–exocrine interface.
Clinical Implications: If validated in humans, targeting β-cell CCK signaling or its induction pathways (e.g., JNK/cJun) could offer prevention or adjunct therapy strategies for obesity-associated PDAC. Risk stratification might incorporate endocrine markers beyond insulin.
Key Findings
- β-cell CCK expression was necessary and sufficient for obesity-associated PDAC progression in mice.
- CCK expression, rather than insulin, correlated strongly with enhanced tumorigenesis.
- Obesity expanded postnatal immature β cells that adopted CCK via stress-responsive JNK/cJun signaling.
- CCK-dependent perturbations of peri-islet exocrine transcriptional states promoted islet-proximal tumor formation.
Methodological Strengths
- Multi-modal mechanistic approach including single-cell RNA-seq, in silico archetypal/trajectory analysis, and in vivo lineage tracing
- Causal interrogation of endocrine drivers using genetic and functional perturbations in relevant obesity models
Limitations
- Findings are derived from murine models; human validation is pending.
- Translation of β-cell CCK targeting to safe, effective human interventions remains uncertain.
Future Directions: Validate β-cell CCK induction and signaling in human islets and PDAC, test pharmacologic CCK/JNK-cJun blockade, and develop biomarkers for endocrine-driven peri-islet tumorigenesis.
Pancreatic endocrine-exocrine crosstalk plays a key role in normal physiology and disease and can be altered by host metabolic states, such as obesity. Classically, endocrine islet beta (β) cell secretion of insulin is thought to promote the development of obesity-associated pancreatic adenocarcinoma (PDAC), an exocrine cell-derived tumor. Here, we show that β cell expression of the peptide hormone cholecystokinin (CCK) is necessary and sufficient for obesity-associated PDAC progression in mice and that CCK expre
2. An extracellular vesicle-mediated mitochondrial transfer network critical for testosterone synthesis.
The study identifies an extracellular vesicle (EV)-mediated mitochondrial transfer and disposal network between Leydig cells and testicular macrophage subpopulations, maintaining mitochondrial homeostasis necessary for sustained testosterone synthesis. Leydig cells export defective mitochondria via EVs for clearance by CD206+ macrophages.
Impact: Revealing organelle-level crosstalk that safeguards steroidogenesis advances fundamental endocrinology and suggests macrophage–Leydig interactions as therapeutic targets in hypogonadism.
Clinical Implications: Therapeutic strategies that modulate EV-mediated mitochondrial quality control or macrophage subpopulations may help preserve or restore testosterone production in testicular dysfunction.
Key Findings
- Identified an EV-mediated mitochondrial transfer network between Leydig cells and distinct testicular macrophage subpopulations.
- Leydig cells release EVs containing defective mitochondria that are cleared by CD206+ macrophages.
- This intercellular pathway supports mitochondrial homeostasis critical for sustained testosterone synthesis.
Methodological Strengths
- Cell-type specific dissection of Leydig–macrophage interactions with organelle-level resolution
- Convergent mechanistic evidence supporting EV-mediated mitochondrial quality control
Limitations
- Predominantly preclinical evidence; human validation and translational feasibility remain to be established.
- Incomplete mechanistic details in the summary may underrepresent bidirectional mitochondrial exchange.
Future Directions: Validate the EV-mediated mitochondrial network in human testes, map macrophage subsets functionally, and test interventions that enhance mitochondrial quality control to support steroidogenesis.
Testosterone production by testicular Leydig cells (LCs) in male mammals is energetically demanding and prone to mitochondrial damage. Despite these challenges, LCs exhibit remarkable longevity and minimal turnover, suggesting the existence of specialized mechanisms that maintain LC mitochondrial homeostasis under such constrains. Here we identify a mitochondrial transfer network between LCs and different testicular macrophage (tMac) subpopulations. Leydig cells release extracellular vesicles containing defective mitochondria, which are eliminated by CD206
3. Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation.
In a target-trial emulation of 314,699 adults with T2D and moderate cardiovascular risk, glimepiride had the lowest 1-year MACE risk, while glipizide had the lowest severe hypoglycemia risk; glyburide performed worst on both outcomes. Advanced causal methods (IPTW with super learner) strengthen internal validity.
Impact: Within-class comparative safety at scale provides actionable guidance when sulfonylureas are used, balancing cardiovascular and hypoglycemia risks.
Clinical Implications: When selecting a sulfonylurea, glimepiride may be preferred for minimizing MACE, whereas glipizide may be favored when severe hypoglycemia risk predominates; glyburide should generally be avoided, especially in higher-risk patients.
Key Findings
- Glimepiride was associated with the lowest 1-year MACE risk among sulfonylureas.
- Glipizide had the lowest severe hypoglycemia risk; glyburide had higher risks for both outcomes.
- IPTW with super learner-based propensity scores enabled robust target-trial emulation across 314,699 patients.
Methodological Strengths
- Very large, nationally representative claims datasets with target-trial emulation
- Advanced causal inference (IPTW, super learner) and time-to-event modeling
Limitations
- Observational design with potential residual confounding and misclassification.
- Dose, adherence, and over-the-counter factors may be incompletely captured in claims data.
Future Directions: Pragmatic head-to-head RCTs comparing sulfonylureas, subgroup analyses by CKD/age/ethnicity, and evaluation of dose-response and combination regimens.
INTRODUCTION: To examine within-class sulfonylurea safety, we compared risks of major adverse cardiovascular events (MACE) and severe hypoglycemia among adults with type 2 diabetes (T2D) and moderate cardiovascular risk following sulfonylurea initiation. RESEARCH DESIGN AND METHODS: We conducted a target trial emulation including adults ≥21 years old with T2D and moderate cardiovascular risk who initiated glimepiride, glipizide or glyburide between 2014 and 2021, using claims data from Optum Labs Data Warehouse and the Medicare fee-for-service 100% sample. Study outcomes were MACE (primary), expanded MACE and its components and emergency department or hospital encounters for hypoglycemia, ascertained during follow-up through 2022. Inverse probability of treatment weighting (IPTW) was applied using propensity scores estimated using the super learner ensemble, and outcomes were examined using IPTW Cox proportional hazards models. RESULTS: The weighted study cohort comprised 314 699 patients (mean age 66.9 years, 52.0% men, 76.6% non-Hispanic white). At 1 year, MACE was experienced by 2.5%, 2.7% and 2.8% of patients starting glimepiride, glipizide and glyburide, respectively. Compared with glimepiride, glyburide and glipizide were associated with higher risk of MACE (HR 1.10, 95% CI 1.05 to 1.16 for glyburide; HR 1.05, 95% CI 1.03 to 1.07 for glipizide). At 1 year, severe hypoglycemia was experienced by 0.3%, 0.3% and 0.4% of patients starting glimepiride, glipizide and glyburide, respectively. Glyburide was associated with a greater risk of severe hypoglycemia compared with glipizide (HR 1.43, 95% CI 1.23 to 1.65), while glipizide was associated with a lower risk compared with glimepiride (HR 0.82, 95% CI 0.77 to 0.87). CONCLUSIONS: Among adults with T2D and moderate cardiovascular risk, glimepiride was associated with lowest risk of MACE and glipizide with lowest risk of severe hypoglycemia. These results can help inform treatment selection if sulfonylureas are used for glucose-lowering.